Common Peptide Myths
A quick-reference myth-vs-fact list. Each row links to a fuller explainer where one is available on this site.
Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.
Myth: Research peptides are basically the same as licensed medicines.
Reality: They are not. Pharmaceutical-grade products are produced under GMP with sterility, endotoxin, and consistency controls. Research-grade is not.
Read more — Research grade is not safe →Myth: If the COA shows 99% purity, the peptide is safe to use.
Reality: Purity is a chemical measurement. It does not address sterility, endotoxin, residual solvents, or stability.
Read more — Purity, sterility, endotoxin →Myth: Animal studies prove the peptide works in humans.
Reality: They do not. Translation from animal models to humans fails the majority of the time.
Read more — Animal vs human →Myth: Stacks work better than single peptides because of synergy.
Reality: Synergy is a specific pharmacological claim that has rarely been demonstrated for peptide stacks. Most stacks are inferred from monotherapy data.
Read more — Synergy: assumed vs demonstrated →Myth: ‘Research use only’ means it is legal for me to use.
Reality: The label is not the legal status. UK medicines law looks at intended use and claims, not packaging.
Read more — What RUO means in the UK →Myth: There are no reported side effects, so it is safe.
Reality: Absence of reports often reflects absence of reporting infrastructure, not absence of harm.
Read more — Adverse events & safety signals →Myth: If celebrities or athletes use it, it must work.
Reality: Testimonial is not evidence. At the elite level, peptides are tightly anti-doping-controlled.
Myth: Peptides are natural, so they cannot be harmful.
Reality: Many endogenous peptides become toxic, immunogenic, or dysregulating when administered exogenously at non-physiological doses.
Read more — Immunogenicity →